Brief: Nanexa Says Nex-20 Phase 1 Study Confirms Controlled Release Of Lenalidomide

Nanexa AB

22/08/2023 07:15

Aug 22 (Reuters) - Nanexa AB  NANEXA.ST :
    * NANEXA OBTAINS PHARMACOKINETIC DATA FROM THE NEX-20 PHASE
1
STUDY CONFIRMING CONTROLLED RELEASE OF LENALIDOMIDE
    * HUMAN PHARMACOKINETIC DATA IN STUDY SHOWS PLASMA CURVE OF
21
DAYS CONTROLLED BY RELEASE FROM PHARMASHELL
    * LOW INITIAL RELEASE OF TOTAL DOSE WAS OBSERVED IN FIRST
DAY
    * TOTAL EXPOSURE IN PLASMA (AUC) WAS CONFIRMED TO INCREASE
WITH
INCREASING ADMINISTERED DOSE
    * FINAL COMPILATION OF SAFETY AND TOLERABILITY DATA WILL BE
DONE
AFTER LAST FOLLOW-UP VISITS FOR LAST DOSE GROUP IN OCTOBER
    * LOCAL ADVERSE EVENTS REPORTED TO DATE WITH NEX-20 HAVE
BEEN
LIMITED AND TRANSIENT INJECTION SITE REACTIONS
    * UNEXPECTED SYSTEMIC OR SEVERE SIDE EFFECTS HAVE BEEN
REPORTED
DURING STUDY SO FAR

Source text for Eikon:  ID:nMFNZtkcc 
Further company coverage:  NANEXA.ST 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;))